Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bevakat bolag.

Datum Källa Rubrik Typ Alternativ
2023-01-24 Intervacc Intervaccs forskningschef Dr Andrew Waller presenterar på FEEVA European Horse Welfare Symposium i Amsterdam Pressreleaser Ladda ner | Visa Stäng
2023-01-24 Intervacc Intervacc's Chief Scientific Officer Dr Andrew Waller presents at the FEEVA European Horse Welfare Symposium in Amsterdam Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 24 Jan 2023 | Intervacc

Intervacc’s Chief Scientific Officer Dr Andrew Waller presents at the FEEVA European Horse Welfare Symposium in Amsterdam

”It’s a fantastic opportunity to speak about equine strangles directly to the core members and the extended network of FEEVA, who are all equine veterinarians from Europe with a passion for horse welfare. I’m really excited to be able to discuss the new tools that can prevent this terrible disease and reduce the suffering it causes to horse populations in the EU and throughout the world”, says Dr Andrew Waller, Chief Scientific Officer at Intervacc. ”2022 was a tough year for strangles cases and we’ve already seen several fatal cases of strangles in 2023. I’m really looking forward to working with vets throughout Europe to begin reversing this trend.”

FEEVA is the umbrella equine veterinary association in Europe, founded 1998 and now representing 20 member countries and more than 7000 equine veterinarians. Today FEEVA has established working groups on Medicines, Horse Welfare, Disease Surveillance and Pre-Purchase Examination and has a mission to be the leading voice of European equine veterinarians guarding both the equine veterinary profession and horse welfare.

Dr Andrew Waller studied the evolution, transmission, and prevention of Streptococcus equi and Streptococcus zooepidemicus for over 17 years in his role as Head of Bacteriology at the Animal Health Trust. He collaborates with world leading researchers in over 20 countries around the world, has published over 80 peer-reviewed papers on streptococcal infections of animals and has utilised these research findings to develop novel diagnostic tests and vaccines with which to improve animal health. Andrew joined Intervacc in 2020 where he continues to work towards improving the health of animals.

Strangles, caused by Streptococcus equi, remains one of the most prevalent infectious diseases of horses worldwide. The transmission of S. equi is facilitated by its ability to persist within the guttural pouches of recovered horses, presenting a challenge to the diagnosis, treatment, and prevention of infection. Andrew’s presentation will describe how this host-restricted pathogen establishes infection and evades host immune responses to be transmitted to naïve animals. The diagnosis, treatment, and prevention of strangles provide opportunities to break the cycle of infection towards the eradication of S. equi from premises with endemic infection. Andrew will describe the latest advances in diagnostic and preventative measures towards improving the health of horses.

For more information please contact:

Andreas Andersson, CEO

Phone: +46-8-120 10 601, cell +46-73-335 99 70
E-mail: andreas.andersson@intervacc.com

The information was submitted for publication, through the agency of the contact person set out above on January 24, 2023, 13.00 CET.

About Intervacc

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company’s vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company’s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se,Phone: +46 (0)8 – 684 211 10

2023-01-23 Intervacc Intervaccs forskningschef Dr Andrew Waller presenterar på Veterinary Sport Horse Congress i Amsterdam Pressreleaser Ladda ner | Visa Stäng
2023-01-23 Intervacc Intervacc's Chief Scientific Officer Dr Andrew Waller presents at the Veterinary Sport Horse Congress in Amsterdam Pressreleaser Ladda ner | Visa Stäng
2022-12-19 Intervacc Intervacc och Sveriges lantbruksuniversitet, SLU, förnyar flerårigt samarbetsavtal för vidareutveckling av vacciner inom djurhälsa Pressreleaser Ladda ner | Visa Stäng
2022-12-19 Intervacc Intervacc and the Swedish University of Agricultural Sciences, SLU, extends a multi-year contract for the development of innovative animal health vaccines Pressreleaser Ladda ner | Visa Stäng
2022-12-13 Intervacc Intervacc: Strangvac, a vaccine against equine strangles released for sales in Italy Pressreleaser Ladda ner | Visa Stäng
2022-12-13 Intervacc Intervacc: Strangvac, ett vaccin mot kvarka, frisläppt för försäljning i Italien Pressreleaser Ladda ner | Visa Stäng
2022-11-28 Intervacc Intervacc: Strangvac, a vaccine against equine strangles, is now available for sale in Poland Pressreleaser Ladda ner | Visa Stäng
2022-11-28 Intervacc Intervacc: Försäljningsstart i Polen för Strangvac, ett vaccin mot kvarka Pressreleaser Ladda ner | Visa Stäng
2022-11-24 Intervacc Intervacc's Chief Scientific Officer Dr Andrew Waller participate at the Dutch Equine Conference Pressreleaser Ladda ner | Visa Stäng
2022-11-24 Intervacc Intervaccs Chief Scientific Officer Dr Andrew Waller medverkar på Dutch Equine Conference Pressreleaser Ladda ner | Visa Stäng
2022-11-16 Intervacc Intervacc's Chief Scientific Officer Dr Andrew Waller will speak about the prevention of equine strangles at the London Vet Show Pressreleaser Ladda ner | Visa Stäng
2022-11-16 Intervacc Intervaccs Chief Scientific Officer Dr Andrew Waller föreläser om kvarka på London Vet Show Pressreleaser Ladda ner | Visa Stäng
2022-11-15 Intervacc Intervacc: Försäljningsstart för Strangvac i Irland Pressreleaser Ladda ner | Visa Stäng
2022-11-15 Intervacc Intervacc: Strangvac sales to start in Ireland Pressreleaser Ladda ner | Visa Stäng
2022-11-11 Intervacc Nomination Committee appointed in respect of AGM 2023 in Intervacc Pressreleaser Ladda ner | Visa Stäng
2022-11-11 Intervacc Valberedning utsedd inför årsstämma 2023 i Intervacc Pressreleaser Ladda ner | Visa Stäng
2022-11-11 Penser Access Penser Access: Strangvac till försäljning på de viktigaste europeiska marknaderna - Intervacc Analyser Visa Stäng
2022-11-10 Intervacc Intervacc: Interim report January - September 2022 Rapporter Ladda ner | Visa Stäng
2022-11-10 Intervacc Intervacc: Delårsrapport januari - september 2022 Rapporter Ladda ner | Visa Stäng
2022-10-12 Intervacc Intervacc: Strangvac, a vaccine against equine strangles released for sales in Germany, France, Austria and the Benelux Pressreleaser Ladda ner | Visa Stäng
2022-10-12 Intervacc Intervacc: Strangvac, ett vaccin mot kvarka, frisläppt för försäljning i Tyskland, Frankrike, Österrike och Benelux Pressreleaser Ladda ner | Visa Stäng
2022-09-02 Penser Access Penser Access: Intervju med Intervacc - Erik Penser Bank - 1 september 2022 Analyser Visa Stäng
2022-09-01 Penser Access Penser Access: Försäljningen av Strangvac är i gång - Intervacc Analyser Visa Stäng
2022-08-31 Intervacc Intervacc: Delårsrapport januari - juni 2022 Rapporter Ladda ner | Visa Stäng
2022-08-31 Intervacc Intervacc: Interim report January - June 2022 Rapporter Ladda ner | Visa Stäng
2022-08-17 Intervacc Intervacc: Försäljningsstart i Storbritannien för Strangvac, ett vaccin mot kvarka Pressreleaser Ladda ner | Visa Stäng
2022-08-17 Intervacc Intervacc: Strangvac, a vaccine against equine strangles, is now available for sale in the UK Pressreleaser Ladda ner | Visa Stäng
2022-07-26 Intervacc VD och ett antal nyckelpersoner tecknar aktier genom utnyttjande av teckningsoptioner i Intervaccs incitamentsprogram 2019/2022 Pressreleaser Ladda ner | Visa Stäng
2022-07-26 Intervacc The CEO and a number of key personnel acquires shares through the exercise of warrants in Intervacc's incentive program 2019/2022 Pressreleaser Ladda ner | Visa Stäng
2022-07-20 Intervacc Intervacc receives order for Strangvac, a vaccine against the equine disease strangles, from the Dechra Pharmaceuticals PLC Group for launch in selected European countries Pressreleaser Ladda ner | Visa Stäng
2022-07-20 Intervacc Intervacc får order avseende Strangvac, ett vaccin mot kvarka, för lansering i utvalda europeiska länder Pressreleaser Ladda ner | Visa Stäng
2022-07-20 Intervacc Intervacc: Strangvac, ett vaccin mot kvarka, frisläppt för försäljning i Storbritannien Pressreleaser Ladda ner | Visa Stäng
2022-07-20 Intervacc Intervacc: Strangvac, a vaccine against equine strangles released for sales in the UK Pressreleaser Ladda ner | Visa Stäng
2022-06-14 Intervacc Report from Annual General Meeting in Intervacc Pressreleaser Ladda ner | Visa Stäng
2022-06-14 Intervacc Kommuniké från årsstämma i Intervacc AB (publ) Pressreleaser Ladda ner | Visa Stäng
2022-06-13 Penser Access Penser Access: Intervju med Intervacc - Erik Penser Bank - 13 juni 2022 Analyser Visa Stäng
2022-06-13 Penser Access Penser Access: Analytikerpresentation av Intervacc - Erik Penser Bank - 13 juni 2022 Analyser Visa Stäng
2022-06-09 Penser Access Penser Access: Rider in i en ny fas - Intervacc Analyser Visa Stäng
2022-05-31 Intervacc Intervacc: Strangvac, a vaccine against equine strangles, available for sale in Denmark Pressreleaser Ladda ner | Visa Stäng
2022-05-31 Intervacc Intervacc: Strangvac, ett vaccin mot kvarka, tillgängligt för försäljning i Danmark Pressreleaser Ladda ner | Visa Stäng
2022-05-20 Intervacc Intervacc: Interim report January - March 2022 Rapporter Ladda ner | Visa Stäng
2022-05-20 Intervacc Intervacc: Delårsrapport januari - mars 2022 Rapporter Ladda ner | Visa Stäng
2022-05-19 Intervacc Intervacc progresses vaccine to prevent mastitis in dairy cows caused by Staphylococcus aureus Pressreleaser Ladda ner | Visa Stäng
2022-05-19 Intervacc Intervacc gör framsteg i vaccinutvecklingen för att förhindra mastit hos mjölkkor orsakade av Staphylococcus aureus Pressreleaser Ladda ner | Visa Stäng
2022-05-11 Intervacc Intervacc: NOTICE OF ANNUAL GENERAL MEETING IN INTERVACC AB (PUBL) Pressreleaser Ladda ner | Visa Stäng
2022-05-11 Intervacc Intervacc: KALLELSE TILL ÅRSSTÄMMA I INTERVACC AB (PUBL) Pressreleaser Ladda ner | Visa Stäng
2022-05-06 Intervacc Intervacc: The Norwegian Food Safety Authority change their regulations to allow vaccination of horses against equine strangles Pressreleaser Ladda ner | Visa Stäng
2022-05-06 Intervacc Intervacc: Norge ändrar regelverk och tillåter vaccination av hästar mot kvarka Pressreleaser Ladda ner | Visa Stäng
2022-04-29 Intervacc Intervacc: Tillsammans mot kvarka Pressreleaser Ladda ner | Visa Stäng
2022-04-25 Intervacc Intervacc: Positive results in proof-of-concept study to develop a vaccine against Streptococcus suis infection in pigs Pressreleaser Ladda ner | Visa Stäng
2022-04-25 Intervacc Intervacc: Positiva resultat i proof-of-concept studie för att utveckla ett vaccin mot Streptococcus suis-infektion hos grisar Pressreleaser Ladda ner | Visa Stäng
2022-04-06 Intervacc Intervacc publicerar årsredovisning för 2021 Rapporter Ladda ner | Visa Stäng
2022-04-06 Intervacc Intervacc publishes the 2021 Annual Report Rapporter Ladda ner | Visa Stäng

Kommande händelser

17 Feb 2023 | Bokslutskommuniké 2022